RxDoctor Payments Data

Brittany Wyger, MD

Obesity Medicine · Thibodaux, LANPI 1871849620

Payments from drug & device makers

$1,735in general payments, 2019–2025

Across 96 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$494
  • Novo Nordisk$347
  • Lilly USA, LLC$236
  • Amgen$122
  • Takeda Pharmaceuticals U.S.A., Inc.$113
  • Currax Pharmaceuticals LLC$112
  • plus $311 from 9 others

What the payments were for

  • Food & beverage$1,735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few obesity medicine providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,884
Medicare patients
28
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$100,679
MounjaroTirzepatide50$59,417
WegovySemaglutide17$28,735
TrulicityDulaglutide18$18,043
TrintellixVortioxetine Hydrobromide17$8,853
Topiramate77$316
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide11$282
Fluticasone Propionate21$282
Pantoprazole Sodium25$256
Esomeprazole Magnesium11$247
Losartan Potassium14$188
Hydroxyzine Pamoate19$180
Atorvastatin Calcium31$176
Metformin Hcl ErMetformin Hcl26$173
Levothyroxine Sodium25$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$347$129,414107 claims
Lilly USA, LLCMounjaro, Trulicity$236$77,46068 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$113$8,85317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other obesity medicine in Thibodaux

Where these figures come from

Is this you, or does something look wrong? →